Log in

BELLUS Health Stock Price, News & Analysis (OTCMKTS:BLUSF)

Today's Range N/A
50-Day Range
MA: $7.51
52-Week Range N/A
Volume12,020 shs
Average Volume61,933 shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$30,000.00
Book Value$0.25 per share


Net Income$-7,010,000.00
Net Margins-49,910.34%


Market Cap$1.19 billion
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive BLUSF News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUSF and its competitors with MarketBeat's FREE daily newsletter.

BELLUS Health (OTCMKTS:BLUSF) Frequently Asked Questions

What is BELLUS Health's stock symbol?

BELLUS Health trades on the OTCMKTS under the ticker symbol "BLUSF."

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc (OTCMKTS:BLUSF) released its earnings results on Thursday, August, 8th. The company reported ($0.04) EPS for the quarter. The business had revenue of $0.01 million for the quarter. BELLUS Health had a negative net margin of 49,910.34% and a negative return on equity of 48.37%. View BELLUS Health's Earnings History.

When is BELLUS Health's next earnings date?

BELLUS Health is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for BELLUS Health.

Has BELLUS Health been receiving favorable news coverage?

News headlines about BLUSF stock have trended somewhat positive on Sunday, according to InfoTrie. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BELLUS Health earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for BELLUS Health.

Who are some of BELLUS Health's key competitors?

What other stocks do shareholders of BELLUS Health own?

Who are BELLUS Health's key executives?

BELLUS Health's management team includes the folowing people:
  • Roberto Bellini, President, Chief Executive Officer & Director
  • François Desjardins, Vice President-Finance
  • Denis Garceau, Senior Vice President-Drug Development
  • Tony Matzouranis, Vice President-Business Development
  • Sébastien Roy, Secretary

How do I buy shares of BELLUS Health?

Shares of BLUSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

How big of a company is BELLUS Health?

BELLUS Health has a market capitalization of $0.00 and generates $30,000.00 in revenue each year. BELLUS Health employs 10 workers across the globe.View Additional Information About BELLUS Health.

What is BELLUS Health's official website?

The official website for BELLUS Health is http://www.bellushealth.com/.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The company can be reached via phone at 45-0680-4500 or via email at [email protected]

MarketBeat Community Rating for BELLUS Health (OTCMKTS BLUSF)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  49 (Thanks for Voting!)
Underperform Votes:  50 (Thanks for Voting!)
Total Votes:  99
MarketBeat's community ratings are surveys of what our community members think about BELLUS Health and other stocks. Vote "Outperform" if you believe BLUSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLUSF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Featured Article: Momentum Indicators

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel